Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Vanda Pharmaceuticals Inc
Revenue
Vanda Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
Revenue
$192.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
19%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Vanda Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Vanda Pharmaceuticals Inc
Breakdown by Segments
Vanda Pharmaceuticals Inc
Total Revenue:
192.6m
USD
|
Hetlioz:
100.2m
USD
|
Fanapt:
90.9m
USD
|
See Also
What is Vanda Pharmaceuticals Inc's Revenue?
Revenue
192.6m
USD
Based on the financial report for Dec 31, 2023, Vanda Pharmaceuticals Inc's Revenue amounts to 192.6m USD.
What is Vanda Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
19%
Over the last year, the Revenue growth was -24%. The average annual Revenue growth rates for Vanda Pharmaceuticals Inc have been -8% over the past three years , and 19% over the past ten years .